The thesis

Royalty Pharma operates a high-margin royalty model with 8938.0% gross margin and 3215.0% net margin. The company's revenue growth is 16.5% YoY. Despite a DORMANT conviction tier with a composite score of 6/100, analyst consensus rating is BUY. The high valuation at 31.8x P/E raises questions about the sustainability of its growth.

Why now

The current macro context of tightening monetary policy and elevated energy prices may impact consumer discretionary spending, indirectly affecting biopharmaceutical innovation funding. Royalty Pharma's revenue growth of 16.5% YoY is being tested in this environment.

What to watch

Revenue growth trajectory over the next quarter and the success of development-stage product candidates will be key indicators. Changes in analyst consensus rating and conviction score will also signal whether the thesis is playing out.

Key risks

Valuation risk is high given the 31.8x P/E ratio, and execution risk is tied to the success of its development-stage product candidates. Macro risk includes potential reduction in biopharmaceutical innovation funding due to tighter monetary policy.

Theme exposure